Thermo Fisher Scientific completed the acquisition of PPD, Inc.

Waltham, quality

"We are very pleased to officially welcome our PPD colleagues to Thermo Fisher Scientific," said Marc N.

As previously announced, this transaction is expected to contribute $1.

Thermo Fisher continues to expect to achieve approximately US$125 million in synergies in the third year, including approximately US$75 million in cost synergies and approximately US$50 million in adjusted operating benefits

By adding PPD, Thermo Fisher Scientific will provide comprehensive world-class services in the field of clinical development-from scientific discovery, to evaluation of safety, effectiveness and health care results, to management of clinical trial logistics, to drug development and production

With the completion of the transaction, PPD’s common stock will cease trading on the Nasdaq before the market opens today

1 Adjusted earnings per share is a non-GAAP measurement method, excluding certain items detailed in the "Using Non-GAAP Financial Measurement Methods" later in this press release

About Thermo Fisher Scientific

Thermo Fisher Scientific (NYSE: TMO) is the world's leading scientific services company with annual revenues of approximately US$40 billion

Forward-looking statements

This letter contains forward-looking statements, which involve certain risks and uncertainties

Use of non-GAAP financial measures

In addition to financial indicators prepared in accordance with generally accepted accounting principles (GAAP), Thermo Fisher Scientific also uses certain non-GAAP financial indicators, including adjusted earnings per share (EPS) that exclude certain acquisition-related costs, including purchases Revaluation of inventory sales and major transaction costs; restructuring and other costs/income; amortization of related intangible assets; certain other isolated or unpredictable gains and losses that occur again in any regular or predictable manner , Tax regulations/benefits related to previous projects, benefits of tax credit carry-over, the impact of major tax audits or events, benefits of unconsolidated entities, and equity in the results of ceased operations

This press release does not constitute a notice to redeem any PPD notes, or an offer to buy or sell (or solicit an offer to buy or sell)

Media contact: Ron O'Brien Thermo Fisher Scientific Tel: 781-622-1242 Email: ron.

Investor contact information: Rafael Tejada Thermo Fisher Scientific Tel: 781-622-1356 Email: rafael.

Source: Thermo Fisher Scientific